Athersys Inc (ATHX)

2.42
0.13 4.90
NASDAQ : Health Care
Prev Close 2.55
Open 2.58
Day Low/High 2.42 / 2.63
52 Wk Low/High 0.94 / 2.90
Volume 2.50M
Avg Volume 828.80K
Exchange NASDAQ
Shares Outstanding 113.91M
Market Cap 271.11M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of January 2018 Options Trading For Athersys (ATHX)

Investors in Athersys Inc saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Short Interest Makes 21% Move For ATHX

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 866,866 share increase in total short interest for Athersys Inc , to 4,997,005, an increase of 20.99% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Two New Publications Highlight The Potential For MultiStem® Treatment Of Ischemic Stroke

Lancet Neurology/Stem Cells publications provide further clarity of MultiStem mechanisms of benefit - modulating inflammatory response and immune system - enhancing recovery

Overview Of MultiStem® Clinical Trial In Japan Presentation At International Stroke Conference 2017

Details of Healios' Phase II/III trial (HLCM051) being presented by stroke expert and lead investigator Dr. Kyohiro Houkin

Athersys Reports Third Quarter 2016 Results

Athersys Reports Third Quarter 2016 Results

Management to host conference call at 4:30 pm EST today

Athersys Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Study Of MultiStem® Treatment For Ischemic Stroke

Athersys Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Study Of MultiStem® Treatment For Ischemic Stroke

SPA for pivotal registration trial clarifies and de-risks development pathway for stem cell therapy

Athersys Announces Acceptance By PMDA Of Clinical Trial Notification In Japan For Treatment Of Ischemic Stroke With MultiStem®

Athersys Announces Acceptance By PMDA Of Clinical Trial Notification In Japan For Treatment Of Ischemic Stroke With MultiStem®

Study designed to provide confirmatory evidence of safety and effectiveness under Japan's accelerated regulatory pathway for qualified regenerative medicine therapies

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARRS, ATAX, CYRN, DAR, GTIM, MLP, NPTN, RCMT, RDN, SEB, SNE, TISA Downgrades: APEI, ATHX, CFBK, HMHC Initiations: CHCT Read on to get TheStreet Quant Ratings' detailed report:

Athersys Reports Second Quarter 2016 Results

Athersys Reports Second Quarter 2016 Results

Management to host conference call at 4:30pm EDT today

Athersys Joins Russell 3000® Index

Athersys Joins Russell 3000® Index

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATHX, BMY, HDSN, NX, OEC, PMT Downgrades: ALSK, CENX, CLI, EVR, MLP, PII, UFPT Initiations: BPMC, EVA Read on to get TheStreet Quant Ratings' detailed report:

Athersys Reports First Quarter 2016 Results

Athersys Reports First Quarter 2016 Results

Management to host conference call at 4:30pm EDT today

Athersys (ATHX) Strong On High Relative Volume Today

Athersys (ATHX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Athersys (ATHX) as a strong on high relative volume candidate

TheStreet Quant Rating: D- (Sell)